Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare, BGI Partner on Stem Cell Research

NEW YORK (GenomeWeb News) – GE Healthcare and BGI today announced a multi-year research collaboration to explore the underlying genetic variation between ethnically diverse human stem cell lines.

The goal of the deal, whose terms were not disclosed, is to advance the use of stem cell-derived assays in drug discovery and toxicity testing.

The partnership is being carried out in two projects. In the first, BGI will sequence and perform epigenetic analyses of cardiomyocytes and hepatocytes supplied by GE Healthcare Life Sciences in order to map the genetic variation across an ethnically diverse range of stem cell lines, and to investigate the changes that occur during differentiation into specific cell types. This will result in a better understanding of cell models used in drug development, they said.

In the second project, GE will provide BGI an IN Cell Analyzer 2000 system for high content cellular imaging analysis. BGI will use the platform to investigate gene function for a library of cell types that have been previously sequenced by overexpressing or blocking the activity of single genes and observing the effect in select cell populations

"As the pharmaceutical industry seeks to reduce the cost of drug development and to bring more effective, safer drugs to market, the availability of more biologically relevant and predictive cell models is becoming increasingly important," Amr Abid, general manager of Cell Technologies, GE Healthcare Life Sciences, said in a statement. "Our long term vision is to help this process by developing a broad range of Cytiva stem-cell derived assays, to include cell types from a wide diversity of ethnic backgrounds.

In collaboration with BGI, the two partners "will advance our understanding of different stem cell lines, which in turn may in the future help in the global drive to develop new, safer and more effective medicines," he added.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.